Biosynthesis of peptide hormones by pancreatic islet endocrine cells is a tightly orchestrated process that is critical for metabolic homeostasis. Like neuroendocrine peptides, insulin and other islet hormones are first synthesized as larger precursor molecules that are processed to their mature secreted products through a series of proteolytic cleavages, mediated by the prohormone convertases Pc1/3 and Pc2, and carboxypeptidase E. Additional posttranslational modifications including C-terminal amidation of the β-cell peptide islet amyloid polypeptide (IAPP) by peptidyl-glycine α-amidating monooxygenase (Pam) may also occur. Genome-wide association studies (GWAS) have showed genetic linkage of these processing enzymes to obesity, β-cell dysfunction, and type 2 diabetes (T2D), pointing to their important roles in metabolism and blood glucose regulation. In both type 1 diabetes (T1D) and T2D, and in the face of metabolic or inflammatory stresses, islet prohormone processing may become impaired; indeed elevated proinsulin:insulin (PI:I) ratios are a hallmark of the β-cell dysfunction in T2D. Recent studies suggest that genetic or acquired defects in proIAPP processing may lead to the production and secretion of incompletely processed forms of proIAPP that could contribute to T2D pathogenesis, and additionally that impaired processing of both PI and proIAPP may be characteristic of β-cell dysfunction in T1D. In islet α-cells, the prohormone proglucagon is normally processed to bioactive glucagon by Pc2 but may express Pc1/3 under certain conditions leading to production of GLP-1(7-36 NH2 ). A better understanding of how β-cell processing of PI and proIAPP, as well as α-cell processing of proglucagon, are impacted by genetic susceptibility and in the face of diabetogenic stresses, may lead to new therapeutic approaches for improving islet function in diabetes.
these enzymes in prohormone processing in pancreatic islets and in diabetes.
| PROHORMONE CONVERTASE 1/3 "
The prohormone convertase Pc1/3 is critical for proper processing of islet prohormones, and mutations in the Pcsk1 gene are associated with obesity and glucose dysregulation.
"
Pcsk1 (encoding Pc1/3) and Pcsk2 (encoding Pc2) were cloned and characterized around the same time by 2 groups working to identify the enzymes responsible for islet endopeptidase activities, termed proinsulin (PI) processing type 1 endopeptidase and PI processing type 2 endopeptidase, that had been previously described by Davidson et al. 2 While these 2 groups first had separate names for the type 1 endopeptidase-termed Pc1 by Seidah and Chretien, 3 and Pc3 by Steiner 4 -the confusion around this nomenclature was resolved by attributing the name Pc1/3 to the type 1 endopeptidase, while Pc2 was found to be the PI processing type 2 endopeptidase.
Pc1/3 is a calcium-and pH-dependent endoprotease, typically cleaving substrates after paired dibasic residues such as KR or RR. Human proPc1/3 is synthesized as a 753 residue propeptide containing a signal peptide and 4 distinct domains, including an N-terminal prodomain, a catalytic domain, a calcium and pH-sensing P-domain, and a C-terminal domain. The prodomain is autocatalytically cleaved, resulting in active Pc1/3, 5 but the prodomain remains bound, inhibiting Pc1/3 activity. As secretory granules mature and pH lowers towards the optimum for Pc1/3 activity (pH 5-5.5), dissociation of the prodomain activates Pc1/3, and autocatalysis of the Cterminal tail results in a 66 or 74 kDa enzyme with higher activity and lower stability. 6 Pc1/3 activity can be further regulated by the Pc1/3 inhibitor proSAAS, which is highly expressed within the islet and is enriched in β-cell secretory granules as they mature. 7 Although much of what is known about Pc1/3 regulation has been discovered in neuroendocrine cells, a number of informative studies have been carried out in the islet. Pax6 and MafA, critical transcription factors for β-cell identity and function, have been shown to bind the Pcsk1 promoter and positively regulate its transcription. 8, 9 In patients with genetic deficiencies of PAX6, PC1/3 expression is also reduced, resulting in an elevated plasma PI/insulin (PI/I) ratio and mild glucose intolerance. Similar islet dysfunction associated with decreased islet Pcsk1 mRNA expression was also observed in a lossof-function Pax6 mutant mouse. Further, a common variant upstream of the PAX6 gene (rs685428) has been associated with lower islet PAX6 and PCSK1 mRNA. 10 Human islet PC1/3 expression is also negatively correlated with glycated haemoglobin (HbA1c) levels, 10 suggesting an important role for PC1/3 in glucose homeostasis.
PC1/3 expression was recently reported to be reduced in Prader-
Willi syndrome-a syndrome of hyperphagic obesity associated with elevated PI levels. Genetic deletion of paternal SNORD116 in Prader-
Willi syndrome leads to diminished PC1/3 expression, 11 likely via the transcription factor NHLH2 through an unknown mechanism. NHLH2 has been shown to positively regulate PCSK1 transcription through heterodimerization with STAT3 and PCSK1 promoter binding. 12 Genetic deletion of paternal Snord116 in mice similarly leads to reduction of islet Pc1/3 and Pc2 expression, along with increased islet and circulating PI. 11 Mutations in the PCSK1 gene in humans were first discovered in a woman with hyperglycaemia during an oral glucose tolerance test (OGTT), with elevated 2 hours OGTT total and 65,66-split PI, 13 and extremely low circulating mature insulin. Combined with altered neuroendocrine secretion and processing defects, PCSK1 mutations were suspected, and the patient was confirmed to be compound heterozygous for PCSK1 null mutations. 14 PCSK1 inactivating mutations typically present with a phenotype similar to NEUROG3 mutations-early failure to thrive due to malabsorptive diarrhoea despite mostly normal intestinal biopsies. Within the first few years of life, patients then develop obesity despite early growth defects, likely due to altered neuroendocrine prohormone processing. In a retrospective paediatric cohort, 13 patients with homozygous PCSK1 mutations were identified, along with 12 new PCSK1 mutations. PI was elevated in all patients assayed, and most patients developed diabetes insipidus.
GWAS have identified PCSK1 single nucleotide polymorphisms (SNPs) associated with obesity, lowered fasting glycaemia, elevated fasting PI, impaired glucose tolerance and increased glucosestimulated PI secretion. 15 The lowered fasting glycaemia may be accounted for by the longer circulating half-life of PI, which retains partial activity at the insulin receptor. A striking number of SNPs have been identified in PCSK1, with the non-synonymous variants studied most in depth being rs6232 (N221D; catalytic domain, <5% allele frequency) and linked rs6234/rs6235 (Q665E/S690T; C-terminal tail domain, 24% allele frequency) ( Table 1 ). Both variants have been found to confer a mild yet significant increase in obesity risk. Still, no increase in diabetes risk has been found in carriers of PCSK1 SNPs.
Pcsk1-null mice were first generated in 2002 through deletion of Pcsk1 promoter elements and the first exon (Table 2 ). In addition to substantial prenatal lethality of homozygous-null animals, by 7 days of age only 7 of the 21 mice born survived. By 6 weeks of age null mice displayed a body weight of only 60% of their littermate control mice, 30 unlike the obesity observed in PCSK1-null humans. Similar to humans, the Pcsk1-null mice had mild diarrhoea, and no gross histological abnormalities of the gastrointestinal system. Interpreting metabolic phenotypes in global Pcsk1 deletion is challenging due to Pc1/3's broad neuroendocrine expression. However, a distinct islet pathology was observed that mirrored human pathology. Intact PI accounted for 87% of pancreatic and 91% of serum total insulin in Pcsk1-null mice, while heterozygous mice displayed 12.3% and 12.2%, and wild-type mice displayed 5.5% and 2.5%. 31 Surprisingly, Pcsk1-null and wildtype mice had comparable glucose tolerance, while heterozygous mice had mild glucose intolerance, possibly due to mild obesity and insulin resistance in the heterozygous mice. Pcsk1-null β-cell secretory granules appeared less mature (less dense with smaller halos), while α-cell granules seemed unchanged. Lloyd et al 33 generated a Pcsk1
N222D
mouse in a mutagenesis screen for obesity genes that more closely resembles the Pcsk1-null clinical presentation in humans. This novel
Pcsk1 mutant mouse may provide a better model for genetic PCSK1 deficiency in humans. However, tissue-specific Pcsk1 deletion will ultimately be required to study the intricate role Pc1/3 is playing in each endocrine tissue, particularly in the islet.
| PROHORMONE CONVERTASE 2
Similar to Pc1/3, Pc2 is synthesized as proPc2, containing 4 major domains: a prodomain, a catalytic domain, a pH and calcium-sensing P-domain, and a C-terminal domain. After signal peptide cleavage, proPc2 autocatalytically cleaves its prodomain, which remains bound as an inhibitor, resulting in mature (64 kDa) Pc2. Cleavage may additionally occur in the C-terminal domain resulting in a smaller, yet still active mature peptide. In contrast to proPc1/3, proPc2 maturation requires assistance of the chaperone protein 7B2 to produce active Pc2. 7B2 plays a dual role in Pc2 maturation-while it is essential for Pc2 activity, a 31-residue fragment of 7B2 is also a potent inhibitor of Pc2 activity. As the pH lowers in maturing secretory granules, 7B2
and its prodomain dissociate, resulting in mature, active Pc2. Thus, errors in both Pc2 and 7B2 production and maturation can impact Pc2 activity.
Pcsk2 transcription is positively regulated by Creb, Neurod1 and (Table 1) .
PCSK2 polymorphisms may not be as well characterized as PCSK1
polymorphisms due in part to the rarity of PCSK2 protein-coding variants. A non-synonymous PCSK2 variant was found enriched in an Old
Order Amish population (R430W variant rs200711626). 23 Although not significant (likely due to low power from infrequency of the allele), R430W was almost twice as prevalent in T2D individuals within this population. Further characterization of this allele found no difference in enzymatic activity or secretion, although R430W did broaden the PC2 pH optimum suggesting it induces a mild conformational change.
Further characterization of rare PCSK2 variant activity in this study found highly deleterious effects of point mutations in PCSK2, indicating that similar to PC1/3, single amino acid changes can greatly affect PC2 function. Given the sensitive regulation of PC2 and associations of PCSK2 non-protein coding variants with T2D, glucose tolerance and insulin production, it seems likely that islet PC2 activity plays a role in both increasing and decreasing diabetes susceptibility.
Pcsk2-null mice were generated in the late 1990s through insertion of a neomycin resistance cassette in exon 3. Despite distribution throughout much of the endocrine and neuroendocrine systems, Pcsk2-null mice have a relatively mild overall phenotype, appearing normal at birth, followed by postnatal-reduced growth rate and hypoglycaemia. 35 Despite Pc2's role in neuropeptide maturation, global Pcsk2 deletion is visibly disruptive within the islet. Pcsk2-null mice have elevated islet proglucagon, prosomatostatin and PI, as well as a striking α-and δ-cell hyperplasia, islet neogenesis and increased total β-cell mass in the pancreas (although the ratio of β-cells to other islet endocrine cells was still decreased). 35, 36 Due to the requirement of Pc2 for production of mature glucagon in α-cells, Pcsk2-null mice lack mature glucagon, resulting in hypoglycaemia. Exogenous glucagon administered over 25 days via mini-osmotic pumps normalized euglycaemia in Pcsk2-deficient mice, as well as islet mass and architecture, suggesting that the absence of mature glucagon was responsible for the observed islet phenotype. 45 In Pcsk2-null embryos the development of insulin-positive cells is delayed, and the frequency of insulin and glucagon-positive bihormonal cells is increased. 36 Collectively, the phenotype of the Pcsk2-null mouse suggests an essential role for Pc2 in development, prohormone processing and euglycaemia, particularly in the islet α-cell.
"
Pc2 is essential for normal processing of proglucagon to mature glucagon in α-cells, and absence of Pc2 is associated with hypoglycaemia.
Cpe is widely expressed in neuroendocrine tissues, removes basic residues from prohormones following Pc1/3 or Pc2 cleavage, and its absence is associated with many hormonal abnormalities.
Cpe, also known as enkephalin convertase and carboxypeptidase H, contains 4 major domains: a prodomain, a zinc metallocarboxypeptidase domain, a transthyretin homology domain and an amphipathic helix domain. Like other prohormone processing enzymes, Cpe is synthesized as a large precursor, proCpe. It has been suggested that furin mediates the conversion of proCpe to Cpe in secretory granules in a pH-dependent manner. 46 However, the removal of Cpe's prodomain is not required for its enzyme activity or intracellular trafficking, with comparable enzyme activity and sorting efficiency of proCpe and mature Cpe. 47 Cpe, at an optimal pH of 5.5, removes C-terminal lysine or arginine residue pairs from peptideprocessing intermediates following endopeptidase cleavage. For example, PI is first processed by Pc1/3 and Pc2, exposing Arg-Arg and Lys-Arg sequences. Subsequently, Cpe removes these basic residue pairs to form mature insulin and C-peptide. The C-terminal amphipathic helix domain functions as a membrane anchor for Cpe. Consequently, Cpe was at one time proposed to be the elusive sorting receptor for sorting peptides to the regulated secretory pathway, 48 although this concept has been called into question. 49, 50 Cpe's structure and function have been extensively reviewed elsewhere.
51
CPE is highly expressed in the brain, immune system, pancreas, gastrointestinal tract and reproductive tissues. As it is involved in the processing of the majority of neuropeptides and peptide hormones, genetic CPE defects lead to severe abnormalities in mice and humans (Tables 1 and 2) . A subject with a CPE truncating mutation developed intellectual disabilities, hypogonadotropic hypogonadism, obesity and T2D. 26 The CPE R283W polymorphism, identified in Ashkenazi families with T2D, is associated with elevated plasma PI levels, and earlier onset of T2D. Although mutations in CPE in mice and in humans display remarkably similar neuroendocrine phenotypes, it is challenging to dissect the roles of Cpe at the cellular level because the neuronal system works closely with the endocrine system to regulate the balance of energy intake, storage and expenditure. It is instinctive to speculate that the obese phenotype observed in Cpe-deficient mice stems directly from erroneous processing of weight-regulating neuropeptides such as α-melanocyte stimulating hormone, neurotensin, prothyrotropin, procholecystokinin and cocaine-and amphetamineregulated transcript (CART) peptides, 52 or from a PI processing defect, and the lack of metabolic regulation. The study of tissue-specific deletion of Cpe in mice may provide deeper insight into how the complex phenotype of Cpe-mutant mice and humans arise.
Pam amidates the C-terminus of many neuropeptides and peptide hormone and variants in Pam are associated with impaired insulin secretion and type 2 diabetes.
"
Pam is a multifunctional protein containing 2 enzyme domains: peptidyglycine α-hydroxylating monooxygenase (PHM), and peptidyl-α-hydroxyglycine α-amidating lyase (PAL). These 2 enzyme domains act sequentially to generate C-terminally amidated peptides. First, the glycine-extended peptides are hydroxylated by PHM to form α-hydroxyglycine intermediates in a copper-, oxygen-and ascorbatedependent manner. Because oxygen is a substrate being incorporated into the α-hydrocyglycine intermediates, the lack of molecular oxygen in hypoxic conditions could hinder peptide amidation. 53 The peptidyl α-hydroxyglycine intermediates are subsequently de-alkylated by PAL in the presence of cofactors zinc and calcium. 54 (Table 1 ). In particular, the S539W mutation was associated with increased plasma glucose and decreased insulin levels at 30 minutes following an oral glucose challenge, and was strongly associated with reduced corrected insulin response (CIR) and insulinogenic index. 28 The D563G variant was identified in another European large-scale whole-genome sequencing study, and was shown again to be associated with increased T2D risk. 29 PAM polymorphisms may directly contribute to islet secretory defects, as a recent report showed that human islets from D563G variants have a modest impairment in insulin granule exocytosis.
59
Pam deletion is not well-tolerated in multiple model organisms, 42 
| ISLET ENDOCRINE CELL PROHORMONE PROCESSING
Precise regulation of Pcsk1, Pcsk2, Cpe and Pam within the islet appears to be required for proper islet function, and impairments in any of these processing enzymes is associated with islet dysfunction or diabetes. The requirement of these enzymes for normal production of mature, bioactive islet hormones suggests that they may play a role in diabetes pathogenesis, and conversely may be targets to improve islet function. Here, we discuss processing of the most abundant islet prohormone peptides in islet β-and α-cells.
"
Proinsulin and proIAPP require processing by Pc1/3, Pc2 and Cpe to their mature and biologically active secreted forms. 
| β-cells
β-cells secrete insulin and other hormone peptides to maintain blood glucose homeostasis. 62 The decline of β-cell function and mass in diabetes is closely associated with the development of both T1D 63 and T2D. 64 Pc1/3, Pc2, Pam, Cpe, 7b2 and proSAAS are all highly enriched in mature secretory granules, emphasizing their crucial role in prohormone processing. 65 Publicly available transcriptomic databases of human islet cell gene expression suggest that PCSK1, PCSK2, CPE and PAM are all expressed in β-cells of islets from non-diabetic human donors, 66 with PCSK1 expression higher than PCSK2.
67-69
Expression of prohormone-processing enzymes is dynamically and tightly regulated at the transcriptional, translational and posttranslational levels, and diabetogenic stressors have been shown to affect this regulation. Pc1/3 protein was found to be upregulated in response to acute (90 minutes) high glucose stimulation in rat islets through translational regulation. 70 The lipotoxic stressor palmitic acid reduces mature Pc1/3 and Pc2 protein in MIN6 β-cells through impairments in PC maturation, 72 and induces rapid degradation of CPE in both MIN6 β-cells and human islets. 73 Chronic inflammatory cytokine treatment results in reduced levels of PC1/3 and PC2 in human islets. 74 Islets isolated from mice with β-cell-specific mTOR deletion, sarcoendoplasmic reticulum Ca 2+ ATPase 2 (SERCA2) haploinsufficiency, or on a high-fat diet, as well as human islets from T2D donors, all have reduced CPE levels. [75] [76] [77] Silencing of TCF7L2 (a T2D susceptibility gene) in human islets also leads to reduced PSCK1 transcript levels. 78 This small sample of evidence from a large body of research highlights the impact diabetogenic stressors have on the regulation of prohormone processing in human islets and common diabetes research models.
Loss of PC expression in vitro may be alleviated with chemical chaperones to reduce cytokine-induced ER stress, slowing the loss of PC1/3 and PC2 expression in human β-cells. 79 Expression of prohormone processing enzymes may also be a reflection of β-cell health and maturity; a recent report suggests that highly blood-perfused rodent islets have higher Pcsk1 and lower Pcsk1n transcript levels. 80 
PCSK1
expression increases in human embryonic stem cell-derived β-cells as they differentiate towards mature insulin-producing cells. 81 In addition, PC1/3 protein is co-localized primarily with insulin-and not glucagon-positive cells, suggesting PC1/3 is an indicator of β-cell identity. 83 CPE and PAM, although more abundantly expressed in human β-cells than PCSK1, have not been established as β-cell maturation markers. These findings suggest a close relationship between β-cell health and maturity with proper peptide-processing machinery.
Indeed, circulating levels of unprocessed or partially processed peptide hormones are found elevated in both T1D and T2D prior to, and early in disease onset, suggesting that impairments in prohormone processing may contribute to diabetes pathogenesis.
| Insulin
Insulin has a critical role in the regulation of blood glucose homeostasis, largely via stimulation of blood glucose uptake and suppression of hepatic gluconeogenesis. Insulin was discovered to be derived from the PI peptide in 1967 by Steiner et al, and found to contain a signal peptide, B-chain, connecting peptide (C-peptide) and A-chain. 83 After removing its signal peptide in the ER, PI is trafficked from the trans-Golgi network (TGN) towards nascent secretory granules. It is classically thought that Pc1/3 acts first to cleave the B-C junction (C-terminal of Arg31-Arg32), followed by Pc2 cleavage at the C-A junction (C-terminal of Lys64-Arg65). 41, 96 and PI/I along with the PI/C-peptide (PI/C) ratios are elevated both in subjects with impaired glucose tolerance [97] [98] [99] and T2D. 100 Notably, the PI/I ratio is elevated in the plasma of T2D subjects after acute stimulation of β-cell secretion, indicating that a processing defect must reside in the β-cell. Thus, in T2D and pre-T2D, there is a clear impairment in the processing of PI to insulin.
From Network for Pancreatic Organ Donors with Diabetes
(nPOD) studies, it is becoming recognized that subjects with T1D may have a considerable remaining mass of β-cells; indeed, even longduration T1D patients can have detectable β-cells, and display low but measurable plasma insulin and C-peptide. 101, 102 Circulating PI levels have been found to be disproportionately elevated in established and newly diagnosed T1D subjects, yielding elevated PI/C ratios. 103, 104 In a proportion of individuals with long-standing T1D, PI secretion persists while C-peptide is undetectable. 105 Interestingly, the remission of T1D (patients maintaining normal HbA1c range with lower insulin dosage) is associated with a lowered plasma PI/C ratio, suggesting the residual islets may have better PI processing shortly after T1D diagnosis. 106 Plasma PI/C ratios may thus have potential as biomarkers for disease prediction in T1D, as well as T2D. Indeed, autoantibody-positive subjects have elevated PI/C ratios that appear to increase closer to diagnosis, 107 and the elevated plasma PI/C ratio is associated with the progression of T1D. 108 Histological analysis of PI area in the pancreas of healthy and autoantibody positive subjects revealed that insulin positive area declines as T1D develops, whereas PI area is significantly higher in autoantibody-positive subjects, compared to non-diabetic subjects. 63 The increased PI secretion in T1D subjects appears to involve impairments in PI processing rather than increased PI biosynthesis, since PC1/3 is decreased 109 ; however, the mechanisms leading to impaired β-cell PC1/3 activity remain unknown.
| Islet amyloid polypeptide
Islet amyloid polypeptide (IAPP) is the second most abundant peptide secreted by pancreatic β-cells. It is stored in the same granules as insulin, and accordingly it is secreted along with insulin. The biological actions of IAPP are still not fully understood, but appear to involve central nervous system-mediated induction of satiety, slowing of gastric emptying and potentiation of leptin signalling.
Similar to preproinsulin, the signal peptide of preproIAPP is first removed in the ER, creating the 67-residue IAPP precursor prohormone, proIAPP. We have showed in mice that Pc1/3 first cleaves proIAPP C-terminal, followed by the removal of the paired basic residues by Cpe to generate a processing intermediate. [110] [111] [112] At the Cterminus, the glycine overhang is removed and IAPP is amidated by 
FIGURE 1 Processing of the 2 major β-cell hormones proinsulin and proIAPP. Prohormone convertases PC1/3 and PC2 cleave C-terminal of dibasic sites, followed by removal of the dibasic residue pair by CPE. PAM modifies C-terminal glycine residues to generate an amidated C-terminus showed that the 48 residue proIAPP intermediate (proIAPP ) is present in human plasma, and that the ratio of proIAPP to IAPP is significantly elevated in both T1D subjects and islet transplant recipients. 113 Our studies raise the possibility that as for PI, proIAPP intermediates may have value as biomarkers of β-cell function in diabetes.
Human IAPP is one of many amyloidogenic peptides which can aggregate under physiological conditions resulting in the formation of amyloid fibrils and plaques in situ. Mouse and rat IAPP do not aggregate under physiological conditions, due primarily to 3 proline substitutions at amino acids A25, S28 and S29 in the mature peptide. These same 3 substitutions are present in the pharmaceutical peptide pramlintide, used clinically as an antiobesity agent, which maintains biological activity but prevents its aggregation. The deleterious effects of IAPP aggregation in the pancreas have been well studied, and include direct toxicity to β-cells as well as inducing islet inflammation.
114
Evidence for altered aggregation properties of proIAPP processing intermediates suggests errors in proIAPP processing as a potential mechanism for amyloid-induced islet failure. 115, 116 In cell lines lacking PC expression, transfection of hproIAPP resulted in increased intracellular amyloid deposition. 117 We showed that mouse islets expressing human proIAPP and with genetic deletion of Pcsk2 have increased apoptosis, and that adenoviral overexpression of Pcsk2 partially rescued islet viability. 112 Islets from Pcsk2-null, human proIAPP expressing mice failed earlier when transplanted into diabetic recipient mice, with increased β-cell loss compared to islets from Pcsk2 wild-type donors. These studies suggest that impaired proIAPP processing at the N-terminal cleavage site may lead to accumulation of toxic intermediate forms and β-cell loss and dysfunction. As it is becoming recognized that prefibrillar aggregates of IAPP forms are likely more toxic and pro-inflammatory than mature amyloid fibrils, the altered aggregation kinetics and cytoxicity of these aggregates warrants future study. IAPP species with less propensity to form fibrils may spend more time in toxic oligomeric phases prior to fibril formation. In addition, incompletely processed forms may have a higher tendency to bind to heparan sulphate proteoglycans, a component of islet amyloid, potentially enhancing amyloid plaque deposition. 115, 118 As IAPP aggregates drive inflammation and β-cell dysfunction, a deleterious cycle may perpetuate, wherein (pro)IAPP aggregates lead to β-cell dysfunction and exacerbate processing defects, leading to the production of more incompletely processed forms of proIAPP and further aggregation and islet dysfunction.
"
Incompletely processed forms of proinsulin and proIAPP are secreted by β-cells in both type 1 and type 2 diabetes and may be biomarkers of β-cell dysfunction. and MPGF within the islet and the body. It has been proposed that GRPP can inhibit insulin secretion through cAMP-independent mechanisms (therefore not via GLP1 or glucagon receptors) with a currently unknown receptor. 37 In Pcsk2-null mouse islets, no glucagon is produced, indicating that Pc1/3 has negligible activity at the Pc2 proglucagon cleavage site K82, R83. 127 α-Cell hyperplasia is also observed in Pcsk2-null islets, potentially as a compensatory mechanism for the lack of glucagon production. 35 stress. 34 The importance of stress-induced α-cell Pc1/3 expression was recently shown in a cell-specific Pcsk1 knockout mouse, where α-cell Pc1/3 was relatively dispensable in healthy islets, but in mice challenged with high-fat diet and low dose STZ (a model of islet inflammation and partial β-cell loss), the lack of α-cell Pc1/3 and its accompanying altered proglucagon processing resulted in worsened glucose tolerance and reduced insulin secretion. 130 Pharmacological approaches to induce α-cell Pc1/3 expression are currently being explored, such as GPR142 agonism, highlighting the beneficial effects of this endogenous stress adaptation in islets.
Although Pam is expressed in α-cells, its current role in α-cell function is unknown. GLP-1 amidation seems dispensable for GLP1R binding and signalling, and has not been found to significantly impact GLP-1 stability. Global Cpe disruption in the Cpe fat/fat mouse does not alter glucagon production in α-cells, but leads to elevated C-terminally extended GLP-1. In addition, Cpe processes the inhibitory fragment of 7B2 by removal of 2 C-terminal residues which are critical for its Pc2 inhibition. Interestingly, 7B2 overexpression improves Pc2 activity and glucagon production in α-TC6 cells and cast/cast mice (which have 2.5-fold higher 7B2 expression over B6 mice) have elevated circulating glucagon. 131 This complexity arises because of 7B2's dual role as both an inhibitor of Pc2 and a chaperone essential for Pc2 maturation and activity.
Intricate crosstalk of processing enzymes in α-cells and their dynamic regulation in response to stress to improve islet function has historically proven challenging to study due to the overlap of processing enzymes with the more abundant β-cells, and the wide variety of proglucagon processing products. Global knockout mice have provided clues to aberrant α-cell function with loss of processing enzymes (Table 2) ; however, these models are difficult to fully interpret within α-cells due to the magnitude of neuropathies and endocrinopathies from global deletion.
| Propeptides in δ-and ε-cells
There are a number of other prohormones and propeptides synthe- (A) (B)
FIGURE 2 Differential processing of proglucagon by prohormone convertases PC2 and PC1/3. In islet α-cells, PC2 processing of proglucagon normally leads to production of glucagon and other proglucagon-related peptides. In the presence of diabetogenic stresses, PC1/3 expression in α-cells can result in α-cell production of glucagon-like peptide 1 (GLP-1) and other proglucagon-related peptides. PC1/3 and PC2 cleave C-terminal of dibasic sites, followed by removal of the dibasic residue pair by CPE. PAM modifies C-terminal glycine residues to generate an amidated C-terminus 6 | DISCUSSION AND CONCLUSION While significant knowledge has been obtained from conventional genetic knockout models (Table 2) , we recognize that the reviewed processing enzymes and peptide hormones are also highly expressed in a number of non-pancreatic tissues. New tools such as islet cell type-specific deletion of processing enzymes and prohormones in mice and single cell gene expression analysis will enable furthering this body of research. Patterns of processing enzyme expression in murine models have not always mirrored those in human islets, and moving forward it will be important to include studies with human tissues to build upon the wealth of knowledge generated in cell lines and murine models. The availability of human islets, plasma and pancreatic sections from large consortiums and biorepositories, including tissue from T1D and T2D donors, promises new insight into human islet hormone biosynthesis, and will enhance the translation of findings in model systems. Building on previous publications with our survey of available single-cell RNA-sequencing databases, proSAAS and 7B2 appear highly expressed in all islet cell types, and are intricately linked to prohormone processing. Hence, it is of interest to further dissect the roles of these understudied granin-related peptides in islets and diabetes. In addition to single-cell RNA-sequencing technology, peptidomic assays on single or sorted cells will provide new approaches to thoroughly examine posttranslationally processed forms of endocrine peptides in specific cell compartments under different conditions. 132 In conclusion, proper processing of islet prohormones to their biologically active forms is essential for blood glucose homeostasis.
Genetic and acquired defects in these processes can lead to a host of metabolic disorders. Evidence of incompletely processed islet prohormones in circulation provides a large pool of candidate biomarkers for early diabetes detection. Moreover, the deleterious effects of disrupted prohormone processing in islets may contribute to diabetes pathogenesis, and provide therapeutic targets to improve islet function in diabetes.
